KRAS and metastatic colorectal cancer: That is mutated KRAS has the potential to prevent the mechanism of action of the main drugs that treat metastatic colorectal cancer, which may explain the low results and the absence of a statistically significant difference observed in the mutated KRAS subgroup (Table 1).